

Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Methsuximide
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
ANI Pharmaceuticals Announces FDA Approval and Commercialization of Two ANDAs with CGT Exclusivity
Details : Methsuximide elevates the seizure threshold and reduces the frequency of attacks through depression of nerve transmission in the cortex.
Product Name : Celontin-Generic
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 15, 2023
Lead Product(s) : Methsuximide
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
